Early-Stage Colon Cancer’s Cloak of Invisibility: Unmasking SOX17

Early-Stage Colon Cancer’s Cloak of Invisibility: Unmasking SOX17

Our immune system is complex beyond comprehension. It acts as a vigilant guard, constantly patrolling for and eliminating threats like viruses, bacteria, and even abnormal cells that could turn cancerous. Cancer is a cunning adversary. New research from a collaborative effort by scientists at the Massachusetts Institute of Technology (MIT), Dana-Farber Cancer Institute, Harvard Medical … Read more

Here Is A Promising Non-Toxic CAR-T Therapy Biotech

Here Is A Promising Non-Toxic CAR-T Therapy Biotech

Immix Biopharma (IMMX) is CART-T cell therapy company targeting oncology and immune-dysregulated disease. Immix’s subsidiary Nexcella (94% owned) focuses a CAR-T therapy, NXC-201, which is in clinical trials for the treatment of multiple myeloma and AL amyloidosis (ALA). The company’s other promising therapy, IMX-110, is being investigated in a Phase 1b/2a study for the treatment … Read more

mRNA Vaccine Shows Promise Against Melanoma

mRNA Vaccine Shows Promise Against Melanoma

U.S. pharmaceutical companies Moderna and Merck say a clinical trial for an experimental Moderna mRNA vaccine used in combination with the Merck cancer therapy drug Keytruda reduced the chance of recurrence or death from melanoma by nearly 50%. “As we continue to follow participants in the KEYNOTE-942/mRNA-4157-P201 study, we are excited to see such a … Read more

CG Oncology Enters Bladder Cancer Therapy Space With IPO

CG Oncology Enters Bladder Cancer Therapy Space With IPO

CG Oncology is a biotech company focused on developing innovative treatments for bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Their two main clinical programs involve cretostimogene grenadenorepvec (CG0070), an oncolytic immunotherapy. CG Oncology filed confidentially on October 27, 2023. The company filed publicly this week with the SEC to raise up to $100 million … Read more

Categories IPO

Ohalo Genetics Emerges From Stealth

Ohalo Genetics Emerges From Stealth

Ohalo Genetics is dedicated to accelerating the evolution of crops to create more efficient and sustainable agriculture. They use innovative plant genetic technologies to improve various aspects of crops, including: Yield: They aim to increase crop yields to meet the growing demand for food from a world population that is expected to reach 10 billion … Read more

Drug Discovery and Precision Medicine Focus Of Google Cloud’s AI-powered Solutions

Drug Discovery and Precision Medicine Focus Of Google Cloud’s AI-powered Solutions

Google Cloud recently announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations. The Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and … Read more

Sherlock Biosciences To Bring SynBio Into Homes

Sherlock Biosciences To Bring SynBio Into Homes

It is inspiring to see evidence that the pace of innovation is narrowing the time between scientific curiosity and engineered scaling, leading to potential real world impacts within just a few years. One example is Sherlock Biosceinces. Its CRISPR-based SHERLOCK™ and synthetic biology-based INSPECTR™ will bring together the accuracy of PCR with the convenience and … Read more

Immunotherapy: The Making Of A Revolution

Immunotherapy: The Making Of A Revolution

To learn how something works is to understand how it’s built. How it came to be. That’s true not only if you play a guitar or repair motorcycle engines, but also if you study the biological systems that make life possible. Evolutionary studies, comparing the development of these systems across animals and organisms, are now … Read more

Pfizer Will Collaborate With Beam Therapeutics For In Vivo Base Editing

Pfizer Will Collaborate With Beam Therapeutics For In Vivo Base Editing

Today, Pfizer Inc. and Beam Therapeutics Inc., a biotechnology company developing precision genetic medicines through base editing, announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. Investors should note Pfizer will pay Beam $300 million up … Read more